Last reviewed · How we verify
MIR
MIR is a medication that works by inhibiting the renin-angiotensin system.
MIR is a medication that works by inhibiting the renin-angiotensin system. Used for Hypertension, Heart failure.
At a glance
| Generic name | MIR |
|---|---|
| Sponsor | Rambam Health Care Campus |
| Drug class | Angiotensin receptor blocker |
| Target | AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
MIR is an angiotensin receptor blocker (ARB) that blocks the action of angiotensin II at its receptor, thereby reducing blood pressure and decreasing the workload on the heart.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Dizziness
- Headache
- Cough
- Fatigue
- Nausea
Key clinical trials
- Effects of Bronchial Segmental Endotoxin Instillation in Humans (PHASE2)
- Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study) (NA)
- Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
- Multicenter Validation of the Salivary miRNA Signature of Endometriosis
- Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis (PHASE3)
- AI for Lung Cancer Risk Definition in Computed Tomography Screening Programs
- MIMICC Study in Patients With Colorectal Cancer (NA)
- Lung Cancer Prevention Screening Programme in Italy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MIR CI brief — competitive landscape report
- MIR updates RSS · CI watch RSS
- Rambam Health Care Campus portfolio CI